Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Premium Investments from Pharma Boost Biotech Returns

This article was originally published in Start Up

Executive Summary

Start-Up decided to see how bioceh licensers fared in receiving premium equity investments from their pharmaceutical counterparts four-months post deal signing.

You may also be interested in...

The Drug Delivery Valuation Dilemma

In comparing the increase or decrease in a company's valuation pre and post deal signing, we discovered that drug delivery companies seem to have hit a kind of valuation wall.

Biotech Private Premiums

Contrary to assumptions, public biotech companies can actually sell their equity privately at premiums to their 3-month average trading price. As for illiquidity, the bane of the biotech investor: it may actually help some companies increase their offering prices.

Rx Market Caps–the Flip Side: From Public-to-Private Investment

This month, we compared valuations for those biotech companies which had both gone public in '95 or '96 and had, in 1998, completed a round of private financing. As the amounts of private money raised got larger, so too did market cap valuations. One major reason: the larger the valuation, the more investors are willing to invest.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts